La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sakar Healthcare Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Sakar Healthcare.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.6%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Mar 23

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Mar 02

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Feb 08

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Jan 10

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Dec 14

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Nov 22

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Sakar Healthcare non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NSEI:SAKAR - Stime future degli analisti e dati finanziari passati (INR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	1,555	112	N/A	N/A	N/A
3/31/2024	1,534	117	-351	245	N/A
12/31/2023	1,518	125	N/A	N/A	N/A
9/30/2023	1,480	144	-475	163	N/A
6/30/2023	1,438	127	N/A	N/A	N/A
3/31/2023	1,342	128	-489	333	N/A
12/31/2022	1,302	178	N/A	N/A	N/A
9/30/2022	1,265	139	-568	352	N/A
6/30/2022	1,265	144	N/A	N/A	N/A
3/31/2022	1,291	152	-109	246	N/A
12/31/2021	1,139	80	N/A	N/A	N/A
9/30/2021	1,109	97	-284	368	N/A
6/30/2021	1,054	118	N/A	N/A	N/A
3/31/2021	953	107	-210	146	N/A
12/31/2020	913	118	N/A	N/A	N/A
9/30/2020	870	122	-219	-50	N/A
6/30/2020	884	106	N/A	N/A	N/A
3/31/2020	839	96	55	189	N/A
12/31/2019	851	88	N/A	N/A	N/A
9/30/2019	844	86	N/A	N/A	N/A
6/30/2019	744	78	N/A	N/A	N/A
3/31/2019	688	67	-88	161	N/A
3/31/2018	534	38	N/A	53	N/A
3/31/2017	447	34	N/A	20	N/A
3/31/2016	414	22	N/A	92	N/A
12/31/2015	386	24	N/A	38	N/A
3/31/2015	350	18	N/A	42	N/A
3/31/2014	297	18	N/A	86	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista SAKAR è superiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di SAKAR cresceranno più velocemente del mercato Indian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di SAKAR cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di SAKAR cresceranno più rapidamente del mercato Indian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di SAKAR cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di SAKAR è previsto essere elevato tra 3 anni

Sakar Healthcare Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

First quarter 2025 earnings released: EPS: ₹1.10 (vs ₹1.46 in 1Q 2024)

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2024

Full year 2024 earnings released: EPS: ₹5.64 (vs ₹6.86 in FY 2023)

Investor sentiment deteriorates as stock falls 15%

Third quarter 2024 earnings released: EPS: ₹0.98 (vs ₹2.16 in 3Q 2023)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Second quarter 2024 earnings released: EPS: ₹1.68 (vs ₹1.01 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 20%

New major risk - Financial position

First quarter 2024 earnings released: EPS: ₹1.46 (vs ₹1.65 in 1Q 2023)

New major risk - Share price stability

Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 27%

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2023

Full year 2023 earnings released: EPS: ₹6.59 (vs ₹8.90 in FY 2022)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Third quarter 2023 earnings released: EPS: ₹2.16 (vs ₹0.07 in 3Q 2022)

Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Investor sentiment improved over the past week

Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: ₹1.01 (vs ₹1.44 in 2Q 2022)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.65 (vs ₹1.80 in 1Q 2022)

Sakar Healthcare Limited, Annual General Meeting, Sep 20, 2022

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Full year 2022 earnings released: EPS: ₹8.73 (vs ₹7.09 in FY 2021)

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹1.44 (vs ₹3.04 in 2Q 2021)

Full year 2021 earnings released: EPS ₹7.09 (vs ₹6.43 in FY 2020)

Investor sentiment deteriorated over the past week

With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹6.87 (vs ₹6.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Third quarter 2021 earnings released: EPS ₹1.20 (vs ₹1.48 in 3Q 2020)

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

New 90-day high: ₹107

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Market bids up stock over the past week

New 90-day high: ₹91.65

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

First half earnings released

Market pulls back on stock over the past week

New 90-day high: ₹84.85

New 90-day high - ₹78.70

First quarter earnings released

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita